Department of Medicine and Medical Specialties, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcala de Henares, Spain.
Ramón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain.
Medicina (Kaunas). 2023 Sep 30;59(10):1752. doi: 10.3390/medicina59101752.
The RANK-RANKL-OPG system is a complex signaling pathway that plays a critical role in bone metabolism, mammary epithelial cell development, immune function, and cancer. RANKL is a ligand that binds to RANK, a receptor expressed on osteoclasts, dendritic cells, T cells, and other cells. RANKL signaling promotes osteoclast differentiation and activation, which leads to bone resorption. OPG is a decoy receptor that binds to RANKL and inhibits its signaling. In cancer cells, RANKL expression is often increased, which can lead to increased bone resorption and the development of bone metastases. RANKL-neutralizing antibodies, such as denosumab, have been shown to be effective in the treatment of skeletal-related events, including osteoporosis or bone metastases, and cancer. This review will provide a comprehensive overview of the functions of the RANK-RANKL-OPG system in bone metabolism, mammary epithelial cells, immune function, and cancer, together with the potential therapeutic implications of the RANK-RANKL pathway for cancer management.
RANK-RANKL-OPG 系统是一个复杂的信号通路,在骨代谢、乳腺上皮细胞发育、免疫功能和癌症中起着关键作用。RANKL 是一种配体,它与破骨细胞、树突状细胞、T 细胞和其他细胞表达的受体 RANK 结合。RANKL 信号促进破骨细胞分化和激活,导致骨吸收。OPG 是一种诱饵受体,它与 RANKL 结合并抑制其信号。在癌细胞中,RANKL 的表达通常增加,这可能导致骨吸收增加和骨转移的发展。RANKL 中和抗体,如地舒单抗,已被证明在治疗骨骼相关事件,包括骨质疏松症或骨转移,和癌症方面有效。这篇综述将全面概述 RANK-RANKL-OPG 系统在骨代谢、乳腺上皮细胞、免疫功能和癌症中的功能,以及 RANK-RANKL 通路在癌症管理中的潜在治疗意义。